Rafael Holdings Inc. (RFL)
NYSE NYSE Primary Summary
RFL Chart
Rafael Holdings: The Second Half Of Calendar 2026 Could Define This Company Forever
Rafael Holdings' Phase 3 clinical trial of a drug named Trappsol Cyclo just got over. Results of the trial are expected in the second half of 2026. RFL has a runway of 4 to 5 quarters. RFL could end up borrowing money in the event of trial results getting delayed or FDA approval getting stretched. In my opinion, RFL does present a compelling investment case for risk-appetite investors. Conservative investors should wait until the trial results are out.
Oil prices fall as Hurricane Rafael expected to start weakening
Oil prices fell slightly on Friday as the risk that a hurricane in the Gulf of Mexico will affect U.S. oil and gas output declined while the market continues to weigh how President-elect Donald Trump's policies might affect supplies.
Rafael Holdings Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 50 | $93.5 | $108.75 | $15.25 | 16.31% |
| TGK Thomas G. Kahn KAHN BROTHERS GROUP Inc. | 58,557 | $1.6M | $125,897.55 | -$1.48M | -92.14% |
 Richard Slavik Newbridge Financial Services Group Inc. | 1,500 | $2,475 | $3,232.5 | $757.5 | 30.61% |
| CAL CoreCap Advisors LLC CoreCap Advisors LLC | 82 | $153.34 | $177.94 | $24.6 | 16.04% |
 William Jollie Quent Capital LLC | 466 | $582.5 | $1,018.21 | $435.71 | 74.8% |
Rafael Holdings Inc. (RFL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Rafael Holdings Inc. ever had a stock split?
Rafael Holdings Inc. Profile
| Financial Services Industry | Financials Sector | Howard S. Jonas CEO | NYSE Exchange | 75062E106 CUSIP |
| US Country | 23 Employees | - Last Dividend | 9 May 2025 Last Split | 26 Mar 2018 IPO Date |
Overview
Rafael Holdings, Inc., based in Newark, New Jersey, is primarily focused on holding interests in both clinical and early-stage pharmaceutical companies, alongside commercial real estate assets in the United States and Israel. Operating since its incorporation in 2017, the company functions through two distinct segments: Healthcare and Real Estate. Its principal activities include the development and commercialization of therapeutic products that leverage the metabolic differences between normal and cancer cells. The company's strategic position allows it to contribute significantly to the oncology field through its innovative research and development initiatives.
Products and Services
- CPI-613 (Devimistat): This leading drug candidate is currently in a Phase III clinical study for treating metastatic pancreatic cancer and acute myeloid leukemia. Devimistat represents a novel approach to cancer treatment, focusing on the unique energy metabolism in cancer cells.
- Promitil: A proprietary prodrug form of mitomycin-C, this molecule is engineered for targeted delivery to cancer cells. It has completed Phase 1B clinical studies. Promitil underscores the company's commitment to developing safer and more effective cancer therapies.
- Folate-targeted Promitil (Promi-Fol): Aimed at the local treatment (intravesical) of superficial bladder cancer, Promi-Fol leverages targeted delivery technologies to improve treatment outcomes in bladder cancer. This innovation represents a specialized approach towards cancer therapy, with potential to minimize systemic side effects.
- Promi-Dox: As a highly potent dual drug liposome, Promi-Dox combines MLP and doxorubicin for the targeting of a basket of tumors. This drug is in development stages but signifies the company's efforts in offering more comprehensive cancer treatment solutions.
- Surgical and procedural devices: In addition to its pharmaceutical endeavors, Rafael Holdings is involved in the development of devices for surgical and procedural applications, including orthopedic arthroscopy instrumentation. This diversification showcases the company’s intent to contribute to different facets of healthcare beyond drug development.
